|
|
Robin Parihar, Julie Dierksheide, Yan Hu, William E. Carson
J Clin Invest. 2002;
110(7):983
doi:10.1172/JCI15950
Abstract |
Full text
| PDF

T
he anti-tumor activity of recombinant mAb’s directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets. However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo. We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12. This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes. Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells. Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell–derived cytokines with the capacity to augment anti-tumor immunity. These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb’s might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(11)
| Title and authors |
Publication |
Year |
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
Kory L Alderson, Paul M Sondel
|
J. Biomed. Biotechnol.
|
2011 |
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
Farrukh T Awan, Rosa Lapalombella, Rossana Trotta, Jonathan P Butchar, Bo Yu, Don M Benson, Julie M Roda, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Jones, Joseph Flynn, David Jarjoura, John R Desjarlais, Susheela Tridandapani, Michael A Caligiuri, Natarajan Muthusamy, John C Byrd
|
Blood
|
2010 |
Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K. Tamura, C. Shimizu, T. Hojo, S. Akashi-Tanaka, T. Kinoshita, K. Yonemori, T. Kouno, N. Katsumata, M. Ando, K. Aogi, F. Koizumi, K. Nishio, Y. Fujiwara
|
Annals of Oncology
|
2010 |
The role of cytokine in regulation of the natural killer cell activity
Vladimir Jurisic, Sladjana Stojacic-Djenic, Natasa Colovic, Gordana Konjevic
|
Srp Arh Celok Lek
|
2008 |
Rafting with the IL-12 receptor
D. W. McVicar
|
Blood
|
2008 |
Human natural killer cells.
Michael A Caligiuri
|
Blood
|
2008 |
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
Sri Vidya Kondadasula, Julie M Roda, Robin Parihar, Jianhua Yu, Amy Lehman, Michael A Caligiuri, Susheela Tridandapani, Richard W Burry, William E Carson
|
Blood
|
2008 |
Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System
Gregory B. Lesinski, Sadhana Sharma, Kimberly A. Varker, Piyush Sinha, Mauro Ferrari, William E. Carson
|
Biomed Microdevices
|
2005 |
HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
Serenella M. Pupa, Elda Tagliabue, Sylvie Ménard, Andrea Anichini
|
J. Cell. Physiol.
|
2005 |
Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy
G. B. Lesinski, S. V. Kondadasula, T. Crespin, L. Shen, K. Kendra, M. Walker, W. E. Carson
|
JNCI Journal of the National Cancer Institute
|
2004 |
|